Axcella Therapeutics (AXLA) Corporate Presentation from NobleCon18Research, News and Market Data on Axcella TherapeuticsNobleCon 18 Complete Rebroadcast
|
Access to Exclusive Content. FREE for Registered Users Only.
Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost.
‌
Welcome to the Channelchek Investor Community
We’ve updated the entire site to bring you faster navigation and increased content at every level. Channelchek is now North America’s leading platform for access to regulated and independent company sponsored equity research.
Don't have an account? Join
Forgot passwordBy clicking “Log In” you agree to Channelchek.com Terms of Use and acknowledge that Channelchek.com Privacy Policy applies to you.
Related News
‌
11/4/2024
Basic Materials
Release – Aurania’s Sampling of Sea Bottom Indicates Potential for Greater Extent of Nickel at Corsica
Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) (“Aurania” or the “Company”) reports that further to its news release dated October 3, 2024, Jean-Paul Pallier, P. Geo., VP Exploration...
8 min read
‌
11/4/2024
Technology
Release – AI Integrated into Conduent Life@Work® Connect with Jellyvision and TALON to Educate Employees about Open Enrollment and Maximize Healthcare Benefit Spend
Conduent Incorporated (Nasdaq: CNDT), a global technology-led business solutions and services company, announced the integration of AI-driven solutions by TALON and Jellyvision’s ALEX with its Life@Work Connect Experience Platform, to elevate employee...
4 min read
‌
11/4/2024
Financial Services
Release – SelectQuote, Inc. Reports First Quarter of Fiscal Year 2025 Results
SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the first quarter of fiscal year 2025 of $292.3 million compared to consolidated revenue for the first quarter of fiscal year 2024...
11 min read
‌
11/4/2024
Health
Release – Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it has entered into...
8 min read
Inbox Intel from Channelchek.
Informed investors make more money. And it’s all about timing. Get it when it happens.